glutamic acid dimethyl ether | 40149-68-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: glutamic acid dimethyl ether
• 英文别名: glutamic acid dimethyl ester；dimethyl glutamate；dl-glutamic acid dimethyl ester；Dimethyl DL-glutamate；dimethyl 2-aminopentanedioate
• CAS: 40149-68-6
• 化学式: C₇H₁₃NO₄
• mdl: MFCD01365418
• 分子量: 175.185
• InChiKey: YEJSPQZHMWGIGP-UHFFFAOYSA-N

物化性质

• 沸点：
  224.3±25.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  glutamic acid dimethyl ether 以 甲苯 为溶剂， 反应 3.0h， 以100%的产率得到5-氧代吡咯烷-2-羧酸乙酯
  参考文献：
  名称：

  使用未活化的羧酸锆催化内酰胺的N酰化

  摘要：

  包括表面活性剂，促智药物和杀虫剂在内的许多化学品在其分子结构中均包含N-酰化内酰胺部分。在这项工作中，报道了许多内酰胺与各种未活化的羧酸直接催化N-酰化。评价了几种路易斯酸催化剂在焦谷氨酸甲酯与棕榈酸的N-酰化反应中的活性。锆基催化剂的活性最高。在回流温度下，使用10％摩尔％的均三甲苯中的Zr（丙氧化物）4可获得高达97％的产率，但ZrOCl 2 ·8H 2O被确定为最稳定的催化剂。研究了底物的范围，并成功地将许多内酰胺-羧酸组合物以57-97％的产率转化为所需的产品。该方法为药物阿尼西坦提供了另一种合成途径，可以以84％的产率生产。基于动力学实验，提出了合理的催化机理。

  DOI：

  10.1016/j.tetlet.2018.03.047
• 作为产物：
  描述：

  alpha-酮戊二酸 在 sodium hydroxide 、 sodium tetrahydroborate 、 氯化亚砜 、 titanium(III) chloride 、 L-酒石酸 、 盐酸羟胺 作用下， 以 甲醇 为溶剂， 生成 glutamic acid dimethyl ether
  参考文献：
  名称：

  Synthesis of .alpha.-amino acids by reduction of .alpha.-oximino esters with titanium(III) chloride and sodium borohydride

  摘要：

  DOI：

  10.1021/jo00276a048
• 作为试剂：
  描述：

  3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride 在 glutamic acid dimethyl ether 、 N-羟基丁二酰亚胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.25h， 生成 (S)-2-((1R,2S,6R,7S)-3,5-Dioxo-4-aza-tricyclo[5.2.1.0^2,6]dec-8-en-4-yl)-pentanedioic acid dimethyl ester
  参考文献：
  名称：

  Demonstration of endo-cis-(2S,3R)-Bicyclo[2.2.1]hept-5-en-2,3- dicarbonyl Unit as a Reverse-Turn Scaffold and Nucleator of Two-Stranded Parallel β-Sheets:  Design, Synthesis, Crystal Structure, and Self-Assembling Properties of Norborneno Peptide Analogues

  摘要：

  endo-cis-(2S,3R)-Bicyclo[2.2.1]hept-5-en (norbornene) dicarbonyl unit with a built-in U-architecture has been demonstrated to be an excellent reverse-turn molecular scaffold. A large variety of endo-cis-(2S,3R)-norborneno bispeptides containing almost all of the coded amino acids were synthesized and examined for conformational preferences by H-1 NMR, FT-IR, CD, and X-ray crystallographic studies. While FT-IR and H-1 NMR variable-temperature studies ruled out the presence of any significant amount of intramolecular hydrogen bonding in simple bispeptides (3a-h) (except in Aib bispeptide), the CD studies were clearly in favor of a beta-turn type structure. Single-crystal X-ray studies on Aib, Val and Leu containing norborneno bispeptides (3b-d) provided convincing proof for the presence of reverse-turn conformation. While the interstrand C-alpha-C-alpha' distances (5.2-5.7 Angstrom) were well within the range of those for beta-turn structures, no interstrand intramolecular hydrogen bonding was seen in Val and Leu bispeptides; the Aib bispeptide forms a seven-membered hydrogen-bonded ring, thus, showing that the norbornene (2S,3R)-dicarbonyl template assembles peptide chains in reverse-turn conformation by virtue of its built-in U-shaped architecture at these positions, and hydrogen bonding may not be necessary to stabilize the turn structure. The endo-cis-(2S,3R) orientation of bispeptide chains is essential for turn structure as shown by the crystal structure of trans-(2R, 3R) and trans-(2S,3S) derivative of Val bispeptide wherein the two peptide chains move away from each other with the C-alpha-C-alpha' distance increasing to 7.1-8.2 Angstrom. The norbornene 5,6-double bond was hydrogenated to 5,6-dihydro derivative which showed almost the same CD spectrum as its olefinic analogue. Oxidative cleavage [Ru (VIII)] of the 5,6-double bond in norborneno bispeptides, as demonstrated with Leu bispeptide, afforded novel cyclopentanoid peptide analogues. The promise of norbornene unit as a template for nucleating the formation of two-stranded parallel beta-sheets with minimum structural complexity is shown by the preparation of higher members of norborneno bispeptides with the general structure NBE(Pep)(2) [NBE = endo-cis-(2S,3R)-bicyclo[2.2.1]hept-5-en (norbornene) dicarbonyl unit; Pep = peptide strand with two, three, or four (same or different) amino acid residues]. In H-1 NMR, the high (3)J(HN alpha) values (7.0-9.3 Hz) observed for the amide protons (Table 5) coupled with the presence of medium to strong intrastrand sequential ROE connectivities d(alpha N(i,i+1)) spanning the entire three- or four-residue sequence in the peptide strands of 9a-e and 10 and the exhibition of relatively low-temperature coefficients (d delta/dT = -0.2 to -3.4 ppb/K) for amide protons in DMSO-d(6) solvent (Table 4) clearly suggested that hydrogen-bonded beta-sheet conformers dominate the population. FT-IR and CD studies provided further support for parallel beta-sheet structures. A particularly unique feature of the norborneno bispeptides is their strong tendency to self-assemble in the solid state.Thus, while endo-cis-(2S,3R)-Aib bispeptide (3b) forms 16-membered hydrogen bonded centrosymmetric dimers, the half-ester half-acid and the dicarboxylic acid derivatives of 3b self-assemble to form highly ordered hydrogen-bonded molecular ribbons. The Val and Leu cis-(2S, 3R)-bispeptides organize into hydrogen-bonded chains and the trans isomer of Val bispeptide self-assembles into hydrogen-bonded beta-sheet ribbon.

  DOI：

  10.1021/ja980143+

文献信息

• AZOLE DERIVATIVE, INTERMEDIATE COMPOUND, METHOD FOR PRODUCING AZOLE DERIVATIVE, AGRICULTURAL OR HORTICULTURAL CHEMICAL AGENT, AND PROTECTIVE AGENT FOR INDUSTRIAL MATERIAL
  申请人：Kureha Corporation

  公开号：US20200288714A1

  公开（公告）日：2020-09-17

  It is provided a plant disease controlling agent having low toxicity to human and animals and excellent handling safety, and showing excellent controlling effects on various plant diseases and high antibiotic action to plant disease germs. A compound represented by the following the general formula (I), or an N-oxide or agrochemically acceptable salt thereof.

  提供一种植物病害控制剂，对人类和动物毒性低，具有出色的操作安全性，在各种植物病害上显示出优秀的控制效果，并对植物病原菌具有高抗生素作用。 由以下一般式（I）表示的化合物，或其N-氧化物或农药可接受的盐。
• Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2,4-diaminopyrimidine-based analogues for the selective inhibition of L. major dihydrofolate reductase
  作者：Maria Bibi、Naveeda Akhter Qureshi、Abdul Sadiq、Umar Farooq、Abbas Hassan、Nargis Shaheen、Irfa Asghar、Duaa Umer、Azmat Ullah、Farhan A. Khan、Muhammad Salman、Ahtaram Bibi、Umer Rashid

  DOI：10.1016/j.ejmech.2020.112986

  日期：2021.1

  2,4-diamine, the impact of different amino acids (valine, tryptophan, phenylalanine, and glutamic acid) and two carbon linkers were explored (52-59). The synthesized compounds were assayed against LmDHFR. Compound 59 with the IC50 value of 0.10 μM appeared as potent inhibitors of L. major. Selectivity for parasite DHFR over human DHFR was also determined. Derivatives 55-59 demonstrated excellent selectivity

  为了解决利什曼病，应寻求有效的治疗药物靶标。二氢叶酸还原酶（DHFR）被认为是治疗利什曼病的关键靶标。在当前的研究中，我们感兴趣的是设计和合成针对L. major的针对DHFR的选择性抗叶酸药物。我们专注于基于3,4-二氢嘧啶-2-一和5-（3,5-二甲氧基苄基）嘧啶-2,4-二胺基序的新型抗叶酸药物的开发。对二氢嘧啶（26-30）模板的4-苯环进行了结构活性关系（SAR）研究。对于5-（3,5-二甲氧基苄基）嘧啶-2,4-二胺，研究了不同氨基酸（缬氨酸，色氨酸，苯丙氨酸和谷氨酸）和两个碳连接基的影响（52-59）。针对Lm DHFR测定合成的化合物。化合物59与IC 50 0.10μM的值表现为的强效抑制剂硕大利什曼原虫。还确定了寄生虫DHFR相对于人DHFR的选择性。衍生物55-59对Lm DHFR具有出色的选择性。化合物56（SI = 84.5）和58（SI = 87.5）显示出对Lm
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS
  申请人：Kandula Mahesh

  公开号：US20150133407A1

  公开（公告）日：2015-05-14

  The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of viscid or excessive mucus, cough, inflammation, redness in sore throat, infection in the throat, sore throat, abnormal mucus secretion, impaired mucus transport, allergic rhinitis, asthma, COPD, respiratory muscular disorders and pain in acute sore throat.

  本发明涉及公式I的化合物或其药用可接受的盐，以及它们的聚合物、溶剂化物、对映体、立体异构体和水合物。包含有效量的公式I化合物的药物组合物，以及用于治疗呼吸系统疾病的方法，可以口服、颊部、直肠、局部、经皮、经粘膜、静脉、非肠道给药、糖浆或注射剂的形式制备。此类组合物可用于治疗粘性或过量粘液、咳嗽、喉咙痛的红肿、喉咙感染、喉咙痛、异常粘液分泌、粘液运输受损、过敏性鼻炎、哮喘、慢性阻塞性肺病（COPD）、呼吸肌疾病和急性喉咙痛的疼痛。
• 一种泊马度胺的制备方法
  申请人：杭州和泽医药科技有限公司

  公开号：CN105440013B

  公开（公告）日：2018-10-09

  一种式(VII)所示的泊马度胺的制备方法，包括如下步骤：(1)以式(Ⅰ)所示的3‑硝基邻苯二甲酸酐为原料，与式(Ⅱ)所示的D,L‑异谷氨酰胺或式(III)所示的D,L‑谷氨酸二甲酯在碱性试剂存在下反应得到相应的式(Ⅳ)或式(V)化合物；(2)将式(Ⅳ)或式(V)化合物关环得到式(Ⅵ)化合物；(3)将式(Ⅵ)化合物进行硝基还原得到式(VII)所示的泊马度胺。本发明工艺路线新颖，工艺条件合理，反应步骤短，操作简单，生产成本低，反应收率高，产物质量好，三废低，具有较大的实施价值和社会经济效应。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018096497A1

  公开（公告）日：2018-05-31

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

  该发明涉及化合物或其药用可接受的多型体、溶剂合物、对映体、立体异构体及其水合物。包括有效量的I式、II式、III式、IV式、V式、VI式、VII式、VIII式、IX式或X式化合物的药物组合物，以及用于治疗真菌感染的方法可以制备为口服、颊部、直肠、局部、经皮、经粘膜、含片、喷雾、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。这些组合物可用于治疗真菌感染。